Doximity, Inc. (DOCS)
NYSE: DOCS · IEX Real-Time Price · USD
24.27
+0.45 (1.89%)
Apr 29, 2024, 4:00 PM EDT - Market closed
Doximity Revenue
Doximity had revenue of $468.33M in the twelve months ending December 31, 2023, with 16.58% growth year-over-year. Revenue in the quarter ending December 31, 2023 was $135.28M with 17.37% year-over-year growth. In the fiscal year ending March 31, 2023, Doximity had annual revenue of $419.05M with 21.98% growth.
Revenue (ttm)
$468.33M
Revenue Growth
+16.58%
P/S Ratio
9.67
Revenue / Employee
$479,356
Employees
977
Market Cap
4.53B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 419.05M | 75.50M | 21.98% |
| Mar 31, 2022 | 343.55M | 136.65M | 66.05% |
| Mar 31, 2021 | 206.90M | 90.51M | 77.76% |
| Mar 31, 2020 | 116.39M | 30.69M | 35.82% |
| Mar 31, 2019 | 85.70M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organon & Co. | 6.26B |
| Perrigo Company | 4.66B |
| Lantheus Holdings | 1.30B |
| Haemonetics | 1.27B |
| Merit Medical Systems | 1.26B |
| CRISPR Therapeutics AG | 371.21M |
| Alpine Immune Sciences | 58.88M |
| Krystal Biotech | 50.70M |
DOCS News
- 14 hours ago - Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Doximity, Inc. (DOCS) - Business Wire
- 16 hours ago - Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Northern District of California against Doximity, Inc. - PRNewsWire
- 18 hours ago - DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm - Accesswire
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS - PRNewsWire
- 2 days ago - ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS - PRNewsWire
- 3 days ago - DOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS - PRNewsWire
- 3 days ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Doximity, Inc. (DOCS) Investors - Business Wire
- 4 days ago - Doximity to Release Fiscal 2024 Fourth Quarter and Full Year Results on May 16, 2024 - Business Wire